Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (1), 24-31

Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old

Affiliations

Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old

H Farhangi et al. Iran J Ped Hematol Oncol.

Abstract

Background: Immune thrombocytopenic purpura (ITP) is the most prevalent cause of thrombocytopenia in children. Despite the importance of ITP in children under 2-years old, only a few publications are available in the literature.ITP usually presents itself as isolated thrombocytopenia and mucocutaneous bleeding.

Materials and methods: This study was conducted on 187 under 2-year-old children diagnosed with ITP and treated at Dr. Sheikh Hospital from 2004 to 2011.In this retrospective study, clinical symptoms, laboratory findings, history of viral infections, vaccination history, and treatment efficacy in children under 2-years old with ITP were investigated.Patients were followed for one year after being discharged from the hospital.

Results: The risk of the disease developing into chronic form was higher in older children (0.001). ITP in children under 3-months old was significantly associated with vaccination (p=0.007). There was no significant differences between male and female patients in regards to newly diagnosed ITP, persistent, and chronic disease status (p = 0.21). No significant difference in bleeding symptoms was observed between patients under 3-months old and 3 to 24-months old (p=0.18).

Conclusion: Infantile ITP respond favorably to treatment. The risk of the disease developing into chronic form is higher in 3-to-24-month-old children compared to under-three-month olds.

Keywords: ITP; Intravenous Immune Globulin; Pediatric; Platelet; Vaccination.

Figures

Figure1
Figure1
Different treatment methods used in children with ITP considering bleeding or non bleeding symptoms

Similar articles

See all similar articles

Cited by 1 article

References

    1. Sandoval C, Visintainer P, Ozkaynak MF, Tugal O, Jayabose S. Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. Pediatric Blood & Cancer. 2004;42(1):109–12. - PubMed
    1. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. The lancet. 2001;358(9299):2122–5. - PubMed
    1. Bolton-Maggs P, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. The Lancet. 1997;350(9078):620–3. - PubMed
    1. Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Childrens Hospital of Alabama. Clinical pediatrics. 2004;43(8):691–702. - PubMed
    1. Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. The Journal of pediatrics. 2003;143(5):605–8. - PubMed

LinkOut - more resources

Feedback